Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Who should receive EGFR tyrosine-kinase inhibitors?
Yu HA, Riely GJ. Yu HA, et al. Lancet Oncol. 2012 Nov;13(11):1074-6. doi: 10.1016/S1470-2045(12)70434-5. Epub 2012 Oct 16. Lancet Oncol. 2012. PMID: 23078959 No abstract available.
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Yu HA, et al. J Thorac Oncol. 2013 Mar;8(3):346-51. doi: 10.1097/JTO.0b013e31827e1f83. J Thorac Oncol. 2013. PMID: 23407558 Free PMC article.
Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, Berger MF, Pietanza MC. Varghese AM, et al. Among authors: yu ha. J Thorac Oncol. 2014 Jun;9(6):892-6. doi: 10.1097/JTO.0000000000000142. J Thorac Oncol. 2014. PMID: 24828667 Free PMC article.
140 results